We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Rupert Murdoch’s company had been in talks to sell to rival CoStar in a deal valued in the ‘low billions’ of dollars
Partners will now vote on proposal to split audit from advisory business
Demerged company will aim to start trading next year as it splits from aerospace business
Swiss group takes bold step to focus on faster-growing and higher-margin medicines
Investors should wait for results of leadership change before pursuing a further demerger
Three years after group’s demerger from Prudential, critics say structure does not work
US conglomerate known for Post-it notes and face masks will also spin off healthcare unit
Investors cool on biggest London listing since Glencore in 2011 on worries about inflation and consumer confidence
Vote to separate consumer healthcare paves way for London’s largest stock market listing in a decade
Chief says US group studied past break-ups in its own industry and by other companies such as GE
Spin-off is biggest structural move by oil and gas major in response to pressure to cut emissions
US pharma group to sell down stake in Haleon business after July IPO
Spinning off the business will make more bolt-on deals possible
Toronto-based group to sell quarter of unit by year-end in one of biggest Wall Street listings of year
Higher prices should burnish the proposed steel spin-off
Belgian group seeks to unlock conglomerate discount and add fizz to lagging shares
Canada-based $690bn investment group explores fee-based business spin-off to win over Wall Street
Bluebell Capital Partners says miner should use dual class share structure for spin-off
Unit could be valued at more than $75bn in one of biggest ever Wall Street listings
Falling share price piles pressure on Japanese industrial conglomerate to shed non-core divisions
Business aims to leverage its pharma credentials while appealing to a wider pool of investors
Bluebell Capital says group’s current strategy is ‘morally unacceptable and financially flawed’
Industry could move to zero emission ‘by 2030 or 35’ if infrastructure in place
The role the department store’s physical footprint plays in driving online sales should not be overlooked
Plan to spin off consumer division has failed to thrill investors
UK Edition
